Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung …
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide.
Targeted therapy against the epidermal growth factor receptor (EGFR) is a promising …
Targeted therapy against the epidermal growth factor receptor (EGFR) is a promising …
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
remain the frontline standard of care for patients with EGFR-mutant non-small cell lung …
remain the frontline standard of care for patients with EGFR-mutant non-small cell lung …
[HTML][HTML] Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non …
LJ Hung, PC Hsu, CT Yang, CHS Kuo… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Background: In real-world practice, most patients with lung cancer are diagnosed when they
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …